Tags

Type your tag names separated by a space and hit enter

Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.
J Nucl Med. 2011 Oct; 52(10):1601-7.JN

Abstract

hRS7 is a humanized IgG1 monoclonal antibody directed against the epithelial glycoprotein-1 (EGP-1; also known as TROP2). This antigen is found in many epithelial cancers, including prostate cancer, and therefore this antibody could be suitable for targeting this cancer. In this study, the characteristics of hRS7 for targeting prostate cancer were examined. The potential for immuno-PET with (89)Zr-hRS7 and immuno-SPECT with (111)In-hRS7 was assessed using nude mice with human prostate cancer xenografts.

METHODS

EGP-1 expression was assessed by immunohistology in human primary and metastatic prostate cancer samples and in PC3 xenografts. The optimal antibody protein dose for prostate cancer targeting was examined in nude mice with subcutaneous PC3 xenografts, and then the biodistribution of (111)In-, (125)I-, and (89)Zr-labeled hRS7 was determined in subcutaneous PC3 xenografts at 1, 3, and 7 d after injection. Immuno-PET and immuno-SPECT were performed with (89)Zr-hRS7 and (111)In-hRS7 in mice with subcutaneous and intraprostatic PC3 xenografts, respectively.

RESULTS

Immunohistochemical analysis showed abundant EGP-1 expression in human primary and metastatic prostate cancers and in PC3 xenografts. (111)In-hRS7 and (89)Zr-hRS7 preferentially and specifically accumulated in PC3 xenografts, with tumor uptake as high as 60% injected dose per gram at a protein dose of 0.1 μg per mouse. PC3 tumors in nude mice were clearly visualized with both tracers with immuno-PET and immuno-SPECT.

CONCLUSION

hRS7 shows excellent in vivo tumor targeting in human prostate cancer xenografts. Therefore, hRS7 is a potential vehicle for targeting prostate cancer.

Authors+Show Affiliations

Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. k.vanrij@akf.umcn.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21865288

Citation

van Rij, Catharina M., et al. "Imaging of Prostate Cancer With immuno-PET and immuno-SPECT Using a Radiolabeled anti-EGP-1 Monoclonal Antibody." Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, vol. 52, no. 10, 2011, pp. 1601-7.
van Rij CM, Sharkey RM, Goldenberg DM, et al. Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med. 2011;52(10):1601-7.
van Rij, C. M., Sharkey, R. M., Goldenberg, D. M., Frielink, C., Molkenboer, J. D., Franssen, G. M., van Weerden, W. M., Oyen, W. J., & Boerman, O. C. (2011). Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 52(10), 1601-7. https://doi.org/10.2967/jnumed.110.086520
van Rij CM, et al. Imaging of Prostate Cancer With immuno-PET and immuno-SPECT Using a Radiolabeled anti-EGP-1 Monoclonal Antibody. J Nucl Med. 2011;52(10):1601-7. PubMed PMID: 21865288.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. AU - van Rij,Catharina M, AU - Sharkey,Robert M, AU - Goldenberg,David M, AU - Frielink,Cathelijne, AU - Molkenboer,Janneke D M, AU - Franssen,Gerben M, AU - van Weerden,Wietske M, AU - Oyen,Wim J G, AU - Boerman,Otto C, Y1 - 2011/08/24/ PY - 2011/8/26/entrez PY - 2011/8/26/pubmed PY - 2011/12/13/medline SP - 1601 EP - 7 JF - Journal of nuclear medicine : official publication, Society of Nuclear Medicine JO - J. Nucl. Med. VL - 52 IS - 10 N2 - UNLABELLED: hRS7 is a humanized IgG1 monoclonal antibody directed against the epithelial glycoprotein-1 (EGP-1; also known as TROP2). This antigen is found in many epithelial cancers, including prostate cancer, and therefore this antibody could be suitable for targeting this cancer. In this study, the characteristics of hRS7 for targeting prostate cancer were examined. The potential for immuno-PET with (89)Zr-hRS7 and immuno-SPECT with (111)In-hRS7 was assessed using nude mice with human prostate cancer xenografts. METHODS: EGP-1 expression was assessed by immunohistology in human primary and metastatic prostate cancer samples and in PC3 xenografts. The optimal antibody protein dose for prostate cancer targeting was examined in nude mice with subcutaneous PC3 xenografts, and then the biodistribution of (111)In-, (125)I-, and (89)Zr-labeled hRS7 was determined in subcutaneous PC3 xenografts at 1, 3, and 7 d after injection. Immuno-PET and immuno-SPECT were performed with (89)Zr-hRS7 and (111)In-hRS7 in mice with subcutaneous and intraprostatic PC3 xenografts, respectively. RESULTS: Immunohistochemical analysis showed abundant EGP-1 expression in human primary and metastatic prostate cancers and in PC3 xenografts. (111)In-hRS7 and (89)Zr-hRS7 preferentially and specifically accumulated in PC3 xenografts, with tumor uptake as high as 60% injected dose per gram at a protein dose of 0.1 μg per mouse. PC3 tumors in nude mice were clearly visualized with both tracers with immuno-PET and immuno-SPECT. CONCLUSION: hRS7 shows excellent in vivo tumor targeting in human prostate cancer xenografts. Therefore, hRS7 is a potential vehicle for targeting prostate cancer. SN - 1535-5667 UR - https://www.unboundmedicine.com/medline/citation/21865288/abstract/ L2 - http://jnm.snmjournals.org/cgi/pmidlookup?view=long&pmid=21865288 DB - PRIME DP - Unbound Medicine ER -